{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-26-005487","form_type":"8-K","ticker":"SABS","cik":"0001833214","company_name":"SAB Biotherapeutics, Inc.","filed_at":"2026-01-07T23:59:59+00:00","discovered_at":"2026-05-14T18:02:36.440855+00:00","generated_at":"2026-05-16T11:24:22.671892+00:00","sec_items":["5.02","7.01","9.01"],"event_type":"leadership","sentiment":"positive","materiality_score":0.6,"calibrated_materiality_score":0.6,"confidence":"high","headline":"SAB Bio appoints David Zaccardelli as Chair and Rita Jain as independent director","bullets":["David Zaccardelli, Pharm.D., appointed Chair of the Board effective January 5, 2026; led Ohtuvayre launch at Verona Pharma.","Rita Jain, M.D., appointed independent director; brings autoimmune/inflammatory disease drug development expertise.","Appointments follow RA Capital's nomination rights from July 2025 private placement; CEO Samuel Reich remains on board.","Company advancing SAB-142, a fully human anti-thymocyte immunoglobulin for type 1 diabetes and autoimmune diseases."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-26-005487","json":"https://secwatch.observer/filing/0001193125-26-005487.json","markdown":"https://secwatch.observer/filing/0001193125-26-005487.md","text":"https://secwatch.observer/filing/0001193125-26-005487.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1833214/000119312526005487/0001193125-26-005487-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1833214/000119312526005487/sabs-20260105.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-16T11:24:22.671892+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}